Wednesday, July 05, 2023 2:25:07 PM
Does it really matter if placebo patients were compared? These types of out-of-context fabricated statements are only meant to dissuade superficial retail shareholders.
The JAMA article puts all of this nonsense to bed, and in combination with Checkpoint Inhibitors, DC-Vax L crushes it with OVERALL SURVIVAL of 50% of patients at the 10-year mark !!!!
exwannabe and others just have some ridiculous axe to grind and don't care about misleading folks.
Patients know, the FDA and NIH know (SPORE grants to UCLA), certainly MHRA/NICE know, the Brain Tumor Charity and numerous other cancer centers and their doctors know the promise of DC-Vax from $NWBO. The insiders at NVCR also know it.
Nobel Prize in medicine for Dr. Linda Liau !!!
The JAMA article puts all of this nonsense to bed, and in combination with Checkpoint Inhibitors, DC-Vax L crushes it with OVERALL SURVIVAL of 50% of patients at the 10-year mark !!!!
exwannabe and others just have some ridiculous axe to grind and don't care about misleading folks.
Patients know, the FDA and NIH know (SPORE grants to UCLA), certainly MHRA/NICE know, the Brain Tumor Charity and numerous other cancer centers and their doctors know the promise of DC-Vax from $NWBO. The insiders at NVCR also know it.
Nobel Prize in medicine for Dr. Linda Liau !!!
Bullish
I own NWBO Shares. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
